Meanwhile, growing subsequent evidence suggest that aberrant overexpression of UCA1 is associated with high risk of poor outcome or clinicopathological characteristics in breast cancer, colorectal cancer, bladder cancer, esophageal squamous cell carcinoma, epithelial ovarian cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, prostate cancer and tongue squamous cell carcinoma [11–13, 15–27]. This evidence concerns the gene UCA1 and hepatocellular carcinoma.